mRNA Vaccines and Therapeutics Market Insights: Emerging Trends, Opportunities & Forecast 2034

0
19

IMARC Group, a leading global market research and management consulting firm, has published its latest market intelligence report on the mRNA vaccines and therapeutics market. The global mRNA vaccines and therapeutics market reached a value of USD 60.58 Billion in 2025. IMARC Group expects the market to reach USD 75.11 Billion by 2034, exhibiting a CAGR of 2.30% during 2026-2034.. Growth is driven by rising global demand for rapid-response vaccines, expanding oncology pipelines built around personalized mRNA cancer therapies, sustained investment in lipid nanoparticle (LNP) delivery technologies, and a widening therapeutic reach into genetic disorders, protein replacement, and gene editing.

The market is moving from a pandemic-era identity toward a diversified platform identity. Revenues that were once concentrated in COVID-19 vaccines are being supplemented by respiratory vaccines, self-amplifying mRNA products, and a deep oncology pipeline. Programmability is the central advantage: once a sequence is designed, the same manufacturing logic can be redirected to a new pathogen or a patient-specific tumor profile. Regulators have also become more comfortable with the platform, as seen in the first approval of a self-amplifying mRNA COVID-19 vaccine across the European Union. At the same time, governments in the United Kingdom, the European Union, India, and low- and middle-income countries are funding domestic manufacturing capacity, which is shifting where mRNA products are made and who can make them.

mRNA Vaccines and Therapeutics Market at a Glance:

  • Market Size: USD 60.58 Billion
  • Forecast Market Size: USD 75.11 Billion
  • Growth Rate 2026-2034: CAGR of 2.30%
  • Leading Application: Infectious Disease, with a 38.4% share
  • Leading Vaccine Manufacturing Mode: In-House, with a 64.3% share
  • Second Largest and Fastest-Growing Application: Cancer, with a 28.6% share
  • Dominant Region: Europe, with a 34.6% share, followed by North America at 28.4%

How AI is Reshaping the Future of the mRNA Vaccines and Therapeutics Market

  • AI-Assisted Sequence Design and Computing Infrastructure: BioNTech and its AI subsidiary InstaDeep operate the Kyber supercomputing cluster in Paris, which provides over 200 NVIDIA H100 GPUs and 86,000 CPUs. The cluster supports generative models for protein and antibody design, and for mRNA design work that once required months of laboratory iteration. The approach shortens design cycles and lets teams test far more candidate sequences before committing to wet-lab work.

  • AI-Enhanced Antigen Selection for Emerging Pathogens: In March, Gennova Biopharmaceuticals secured up to USD 13.38 Million from CEPI to develop a self-amplifying mRNA vaccine against the Nipah virus. As part of the project, Gennova will work with the Houston Methodist Research Institute to apply AI to optimize the viral proteins used as vaccine targets. This shows how AI is being paired with lower-dose saRNA platforms to speed up vaccine candidates for diseases that have no approved vaccine.

  • Computational Design of Personalized Cancer Therapies: Individualized neoantigen therapies depend on computational pipelines that read a patient's tumor sequencing data and select the targets to encode. Merck and Moderna's intismeran autogene encodes up to 34 patient-specific neoantigens, and the pivotal melanoma trial enrolled 1,137 patients. As these pipelines scale, the speed and reliability of the design step become a competitive advantage for companies commercializing personalized mRNA medicines.

Grab a sample PDF of this report: https://www.imarcgroup.com/mrna-vaccines-therapeutics-market/requestsample

mRNA Vaccines and Therapeutics Market Trends and Drivers:

The global mRNA vaccines and therapeutics market is expanding as disease burden, platform maturity, and government support converge. Respiratory infections are a persistent demand anchor. In the United States alone, respiratory syncytial virus (RSV) kills up to 10,000 people each year, including 100 to 300 children, and about 1 or 2 of every 100 children are hospitalized with a lower respiratory tract infection caused by RSV in the first six months of life. Oncology is the second major driver. The International Agency for Research on Cancer, part of the World Health Organization, projects global cancer cases will climb to about 35 million new cases in the long term. That outlook is pushing companies like Moderna, Merck, and BioNTech to advance personalized mRNA cancer vaccines, where a single treatment can be built around an individual tumor's mutations.

A structural differentiator is the global push for regional manufacturing and the technology advances that make it feasible. African countries import about 99% of the vaccines they use, and the WHO and Medicines Patent Pool mRNA technology transfer programme was created to change that, with 15 partners across 15 countries receiving foundational mRNA technology from a hub in Cape Town. Self-amplifying mRNA is another structural shift. These platforms replicate inside cells and can deliver comparable immune responses at doses 10 to 100 times lower than conventional mRNA, which reduces the manufacturing burden per dose. Constraints remain: mRNA products require ultra-cold storage between -70°C and -20°C, and a dose of the BioNTech-Pfizer vaccine costs about USD 19.5 in the United States, which limits bulk procurement in lower-income markets.

Manufacturing control and regulatory confidence are the third driver. Moderna, BioNTech, and Pfizer have collectively invested over USD 8 Billion in dedicated in-house mRNA manufacturing infrastructure, which explains why in-house production holds a 64.3% share. Regulators are also building the standards needed to support quality at scale. Examples include marketing authorization for the first self-amplifying mRNA COVID-19 vaccine in the European Union and a new reference material for mRNA quality assessment released by the National Institute of Standards and Technology. These developments set the stage for the regulatory and policy landscape below.

Ask an analyst for customized report: https://www.imarcgroup.com/request?type=report&id=2207&flag=E

Global Regulatory, Trade, and Sustainability Landscape Shaping Demand:

  • World Health Organization and Medicines Patent Pool, mRNA Technology Transfer Programme: The programme is built around a hub at Afrigen in South Africa and now covers 15 partners in 15 countries, including Argentina, Bangladesh, Brazil, Egypt, India, Indonesia, Kenya, Nigeria, Pakistan, Senegal, Serbia, Tunisia, Ukraine, and Vietnam. The European Commission has contributed EUR 40 Million toward establishing the hub. The programme aims to make mRNA manufacturing capacity a more evenly distributed global resource.

  • European Medicines Agency and European Commission: The Committee for Medicinal Products for Human Use issued a positive opinion on KOSTAIVE on December 12, followed by European Commission marketing authorization in February. This was the first self-amplifying mRNA COVID-19 vaccine approved in the European Union, and the authorization is valid across all EU member states and EEA countries. The approval gives a regulatory reference point for other saRNA products.

  • United States Food and Drug Administration: In August, the FDA approved Pfizer-BioNTech's LP.8.1-adapted COVID-19 vaccine, showing that strain-updating mRNA vaccines continue to move through established approval pathways. Merck and Moderna have also said the positive Phase 3 melanoma data will allow them to begin engaging the FDA and other regulators on bringing the combination to the clinic.

  • National Institute of Standards and Technology: In July, NIST launched RGTM 10202 FLuc mRNA, a reference material for quality assessment of mRNA therapeutics. Common reference materials help laboratories compare results, support LNP and mRNA characterization, and speed regulatory harmonization for next-generation products.

Key Government Schemes and Policy Programs Supporting the Industry:

  • India, Mission COVID Suraksha (Department of Biotechnology and BIRAC): The mission funded Pune-based Gennova Biopharmaceuticals' mRNA vaccine candidate HGCO19 with up to Rs 100 crore after the first phase of clinical trials, following earlier seed funding. The Department of Biotechnology also helped establish what it described as a first-of-its-kind mRNA vaccine manufacturing platform in India. That platform has since been extended to saRNA programs against Nipah virus and rabies, supported by CEPI funding of up to USD 16.98 Million.

  • United States, HHS and BARDA Policy Shift: In August, HHS announced a coordinated wind-down of 22 mRNA vaccine development investments under BARDA, worth nearly USD 500 Million, and said no new mRNA-based projects would be initiated by BARDA. Some final-stage contracts, including those with Arcturus and Amplitude, were allowed to proceed to preserve prior taxpayer investment, and HHS said other uses of mRNA technology within the department were not affected. In May, HHS had also terminated a USD 590 Million contract with Moderna for a bird flu vaccine. The shift is moving private and international funding, including CEPI, UK, and EU programs, into a larger role for mRNA development.

  • European Union, HERA and EU FAB: The European Commission pays EUR 160 Million per year to reserve vaccine manufacturing capacity across four EU producers, covering mRNA, vector-based, and protein-based vaccines. The network is designed to maintain capacity for 325 million doses annually in a health emergency. Separately, HERA Invest, a EUR 130 Million top-up funded by EU4Health under InvestEU, provided Ethris with EUR 30 Million in financing to advance respiratory mRNA products.

  • United Kingdom, Strategic Partnerships and the NHS Cancer Vaccine Launch Pad: The government's partnership with BioNTech aims to provide up to 10,000 patients with personalized cancer immunotherapies, backed by a BioNTech investment of GBP 1 Billion over 10 years. The NHS Cancer Vaccine Launch Pad has signed up 30 hospitals and has referred about 550 patients to bowel and skin cancer trials. Moderna's Innovation and Technology Centre at Harwell can produce 250 million vaccine doses a year in a pandemic.

mRNA Vaccines and Therapeutics Industry Segmentation:

The report has segmented the market into the following categories:

Breakup By Vaccine Type:

  • Self-amplifying mRNA-Based Vaccines
  • Conventional Non-Amplifying mRNA-Based Vaccines

Conventional non-amplifying mRNA-based vaccines account for the leading vaccine type segment, supported by their established clinical record, approved COVID-19 and RSV products, and mature manufacturing processes. Self-amplifying mRNA is the emerging alternative, with lower dose levels and manufacturing efficiency demonstrated by KOSTAIVE, the first approved saRNA COVID-19 vaccine, which showed antibody persistence for up to 12 months after vaccination in follow-up analysis.

Breakup By Treatment Type:

  • Bioengineered Vaccine
  • Gene Therapy
  • Gene Transcription
  • Cell Therapy
  • Monoclonal Antibody
  • Others

Bioengineered vaccines lead the treatment type segment, reflecting the commercial scale of approved mRNA vaccines such as Comirnaty and Spikevax and the growing pipeline of individualized cancer vaccines. Gene therapy, cell therapy, and in vivo antibody expression are widening the segment base, as companies apply the same delivery platforms beyond immunization.

Breakup By Vaccine Manufacturing:

  • In-House
  • Out-Sourced

In-house manufacturing dominates with a 64.3% share, as large pharmaceutical companies prioritize proprietary control over mRNA intellectual property, quality oversight, and supply flexibility during outbreaks. Out-sourced manufacturing holds a 35.7% share and is expanding as contract development and manufacturing organizations improve their capabilities, giving smaller biotech firms access to validated mRNA production without heavy capital investment.

Breakup By Application:

  • Cancer
  • Infectious Disease
  • Gene Editing
  • Protein Replacement

Infectious disease leads with a 38.4% share, driven by COVID-19 booster programmes, RSV vaccine rollouts, and influenza mRNA vaccines moving through clinical development. Cancer follows at 28.6% and is the fastest-growing application, supported by Moderna and Merck's positive Phase 3 melanoma trial and BioNTech's personalized pipeline. Gene editing accounts for 18.4% and protein replacement for 14.6%, as mRNA is applied to genetic disorders and enzyme-deficiency conditions that currently rely on expensive recombinant protein infusions.

Breakup By End-User:

  • Hospitals and Clinics
  • Research Organizations
  • Others

Hospitals and clinics hold the leading end-user position, as they are the administration point for vaccination programmes, oncology treatments, and clinical trial participation. The rollout of personalized cancer vaccine trials through networks such as the NHS Cancer Vaccine Launch Pad, which has signed up 30 hospitals, shows how clinical sites are becoming central to mRNA delivery.

Breakup By Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Europe dominates the global mRNA vaccines and therapeutics market with a 34.6% share, anchored by Germany's biotechnology ecosystem, home to BioNTech and CureVac, and by the United Kingdom's NHS-backed personalized cancer vaccine programme. The European Medicines Agency's adaptive licensing pathways and Horizon Europe research funding add to the region's strength. North America follows with a 28.4% share, led by the United States, where Moderna, Pfizer, and Arcturus Therapeutics are based. Asia Pacific holds 22.3% and is the highest-growth frontier, with India, Japan, and South Korea expanding regional mRNA manufacturing capacity.

Competitive Landscape:

The report provides a comprehensive analysis of the competitive landscape in the mRNA vaccines and therapeutics market with detailed profiles of all major companies, including:

  • Arcturus Therapeutics, Inc.
  • BioNTech SE
  • GSK plc
  • Moderna, Inc.
  • Pfizer Inc.
  • Sanofi
  • Merck & Co.

The competitive field is led by a concentrated group of multinational pharmaceutical and biotechnology companies, with Moderna, BioNTech, and Pfizer accounting for the majority of current revenues. Scale and deal-making are shaping positions. BioNTech completed its acquisition of CureVac in an all-stock transaction valued at about USD 1.25 Billion, and Sanofi built its mRNA platform through a USD 3.2 Billion acquisition of Translate Bio. Arcturus, which developed the first approved self-amplifying mRNA COVID-19 vaccine, holds over 400 patents and patent applications across the United States, Europe, Japan, China, and other countries. Merck and Moderna are co-developing intismeran, which has moved from a Phase 2b study to a pivotal Phase 3 trial of 1,137 patients.

Market Concentration Analysis:

  • Moderately Concentrated Core: Moderna, Pfizer-BioNTech, and the CureVac-GSK grouping together account for approximately 64% of current market revenues, mainly through COVID-19 vaccine sales and booster programmes. This gives the market a concentrated revenue base, even as newer segments are still forming.

  • Consolidation Through Deals and Licensing: BioNTech's USD 1.25 Billion acquisition of CureVac, which also resolved a long-running patent dispute, and Sanofi's USD 3.2 Billion Translate Bio purchase show a pattern of larger players absorbing platform and intellectual property assets. Strategic partnerships and licensing are expected to increase as pipelines approach commercialization.

  • Fragmentation in Oncology and Rare Disease, With Regional Champions: The oncology and rare disease segments remain more fragmented, with dozens of biotech firms running early-to-mid stage mRNA programmes. Regional champions are also emerging, including BioNTech in Germany, Moderna and Pfizer in the United States, and Arcturus and CSL with their saRNA joint venture, ARCALIS, in Japan.

What Does The Full Report Cover?

If you are tracking the mRNA vaccines and therapeutics market for investment decisions, market entry planning, competitive benchmarking, or strategic advisory, IMARC Group's report gives you everything in one place:

  • Complete market sizing with revenue forecasts covering the full projection period

  • Quantified growth driver, restraint, opportunity, and challenge analysis across vaccine type, treatment type, vaccine manufacturing, application, end-user, and regional markets

  • Sub-segment breakdowns for self-amplifying and conventional mRNA vaccines, bioengineered vaccines, gene therapy, cell therapy, monoclonal antibodies, in-house and out-sourced manufacturing, cancer, infectious disease, gene editing, and protein replacement

  • Country-level data for the United States, Canada, Germany, France, the United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, and Mexico

  • Competitive profiles of leading companies including Moderna, BioNTech, Pfizer, GSK, Arcturus Therapeutics, Sanofi, and Merck & Co., with strategic landscape assessment

  • Porter's Five Forces, industry value chain analysis, and technology landscape coverage across LNP delivery, AI-assisted sequence design, and manufacturing scale-up

  • Latest innovation trends covering self-amplifying mRNA platforms, personalized cancer vaccines, expansion into rare genetic diseases, and emerging market manufacturing, shaping competition and investment across key regional markets

Recent News and Developments in mRNA Vaccines and Therapeutics Market

  • October: Detailed results from the Phase 3 INTerpath-001 trial showed that adding intismeran autogene, Merck and Moderna's personalized mRNA cancer vaccine, to adjuvant pembrolizumab reduced the risk of recurrence or death by 42% in patients with completely resected high-risk melanoma. Overall survival data remain immature, but the results strengthen the case for individualized neoantigen therapies in earlier-stage cancers.

  • August: Merck and Moderna announced that INTerpath-001, which randomized 1,137 patients with resected stage IIB to IV melanoma, met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival. The companies described it as the first positive Phase 3 result for an individualized neoantigen therapy and for an mRNA-based cancer therapy. The broader program spans nine Phase 2 and Phase 3 trials across melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma.

  • January: BioNTech completed its acquisition of CureVac in an all-stock transaction valued at about USD 1.25 Billion, with CureVac shareholders receiving about USD 5.46 in BioNTech shares per CureVac share. The deal consolidates mRNA intellectual property and adds CureVac's research and manufacturing site in Tübingen to BioNTech's oncology strategy.

  • June: At a meeting alongside the G20 Health Working Group in Johannesburg, leaders from the WHO and Medicines Patent Pool mRNA Technology Transfer Programme set the foundation for its next phase. The programme had progressed technology transfer to eight of its 15 partners in 15 countries, with a focus on building commercially viable mRNA products in low- and middle-income markets.

  • March: Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, secured up to USD 13.38 Million from CEPI to develop a self-amplifying mRNA vaccine against Nipah virus, building on an earlier USD 3.6 Million investment to optimize its saRNA platform. The project uses AI from the Houston Methodist Research Institute to optimize vaccine target proteins, and CEPI has invested over USD 100 Million in Nipah programs overall.

  • February: The European Commission granted marketing authorization to CSL and Arcturus Therapeutics' KOSTAIVE, the first self-amplifying mRNA COVID-19 vaccine approved in the European Union, for individuals aged 18 and above. The authorization is valid across all EU member states and EEA countries, and follow-up analysis showed superior immunogenicity and antibody persistence for up to 12 months compared with a conventional mRNA comparator.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

Key Questions This Report Answers

  • What is the current global mRNA vaccines and therapeutics market size and what is its projected value?

  • Which application segment holds the largest share in the global mRNA vaccines and therapeutics market?

  • What are the key drivers of global mRNA vaccines and therapeutics market growth?

  • Which region dominates the global mRNA vaccines and therapeutics market and why?

  • How are personalized cancer vaccines, self-amplifying mRNA platforms, and AI-assisted sequence design reshaping product development and competitive strategies?

  • Who are the top companies in the global mRNA vaccines and therapeutics market and what are their competitive strategies?

  • What are the investment and market entry opportunities across oncology, rare genetic disease, protein replacement, and regional manufacturing segments?

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Media and Sales Contact

IMARC Group

Email: sales@imarcgroup.com

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104

Cerca
Categorie
Leggi tutto
Networking
Dominique Rogeau: A Psychic Consultant Who Blends Knowledge with Compassion
In the world of psychic readings, technical skill is only part of what makes a practitioner truly...
By TheHouse Look 2025-12-11 10:14:19 0 5K
Altre informazioni
Infrastructure Investment and Industrial Fluid Handling Support the Fiberglass Pipe System Market
Fiberglass pipe systems, often made from glass-fiber-reinforced polymer, offer an alternative to...
By Keshavi Kumari 2026-10-21 11:14:07 0 903
Sports
Reddy Anna ID and Reddybook Access Made Easy
Reddy Anna Login should always be performed through a trusted access Getting started with an...
By reddyanna bookapp 2026-09-24 06:32:34 0 1K
Altre informazioni
U.S. Sports Betting Market: Industry Trends, Dynamics, and Competitive Landscape
The U.S. Sports Betting Market is witnessing significant transformation, shaped by innovation,...
By Priti Jain1999 2026-09-28 09:17:09 0 1K
Altre informazioni
Advanced Gas Metering Infrastructure Market Insights, Remote Monitoring 2035
As per Market Research Future, the Advanced Gas Metering Infrastructure market is...
By Suryakant Gadekar 2026-02-19 13:03:48 0 3K
SocioMint https://sociomint.com